BIOMAT Database Logo BIOMAT Database Logo

Increased plasma levels of urokinase plasminogen activator and matrix metalloproteinase-9 in nonsmall cell lung cancer patients. 2005

Shun-Fa Yang, and Yih-Shou Hsieh, and Chiao-Lin Lin, and Nan-Yung Hsu, and Hui-Ling Chiou, and Fen-Pi Chou, and Shu-Chen Chu
Institute of Biochemistry, Chung Shan Medical University, Taichung 402, Taiwan.

BACKGROUND The involvements of matrix metalloproteinase-9 (MMP-9) and urokinase plasminogen activator (uPA) in the pathogenesis of various types of lung cancers have been established. The aim of the present study was to determine the concentrations of MMP-9 and uPA in the plasma of nonsmall cell lung cancer (NSCLC) patients. METHODS Gelatin zymography and ELISA were used to measure MMP-9 and uPA concentrations, respectively, in 90 NSCLC patients and 50 control subjects. RESULTS Compared with that of control subjects, MMP-9 and uPA levels were significantly higher in the plasma of NSCLC patients (P<0.001 and P<0.01, respectively). Further statistical analysis for clinic pathological parameters revealed that MMP-9 and uPA levels were significantly increased in patients with metastasis (P<0.01 and P<0.05, respectively). Furthermore, the MMP-9 level was significantly different between smokers and nonsmokers (P<0.05) while uPA levels varied between histological types (P<0.05). CONCLUSIONS Plasma MMP-9 and uPA might play an important role in the metastasis of NSCLC by involvement in the processes of invasion and metastasis.

UI MeSH Term Description Entries
D008175 Lung Neoplasms Tumors or cancer of the LUNG. Cancer of Lung,Lung Cancer,Pulmonary Cancer,Pulmonary Neoplasms,Cancer of the Lung,Neoplasms, Lung,Neoplasms, Pulmonary,Cancer, Lung,Cancer, Pulmonary,Cancers, Lung,Cancers, Pulmonary,Lung Cancers,Lung Neoplasm,Neoplasm, Lung,Neoplasm, Pulmonary,Pulmonary Cancers,Pulmonary Neoplasm
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D002289 Carcinoma, Non-Small-Cell Lung A heterogeneous aggregate of at least three distinct histological types of lung cancer, including SQUAMOUS CELL CARCINOMA; ADENOCARCINOMA; and LARGE CELL CARCINOMA. They are dealt with collectively because of their shared treatment strategy. Carcinoma, Non-Small Cell Lung,Non-Small Cell Lung Cancer,Non-Small Cell Lung Carcinoma,Non-Small-Cell Lung Carcinoma,Nonsmall Cell Lung Cancer,Carcinoma, Non Small Cell Lung,Carcinomas, Non-Small-Cell Lung,Lung Carcinoma, Non-Small-Cell,Lung Carcinomas, Non-Small-Cell,Non Small Cell Lung Carcinoma,Non-Small-Cell Lung Carcinomas
D004797 Enzyme-Linked Immunosorbent Assay An immunoassay utilizing an antibody labeled with an enzyme marker such as horseradish peroxidase. While either the enzyme or the antibody is bound to an immunosorbent substrate, they both retain their biologic activity; the change in enzyme activity as a result of the enzyme-antibody-antigen reaction is proportional to the concentration of the antigen and can be measured spectrophotometrically or with the naked eye. Many variations of the method have been developed. ELISA,Assay, Enzyme-Linked Immunosorbent,Assays, Enzyme-Linked Immunosorbent,Enzyme Linked Immunosorbent Assay,Enzyme-Linked Immunosorbent Assays,Immunosorbent Assay, Enzyme-Linked,Immunosorbent Assays, Enzyme-Linked
D005260 Female Females
D005780 Gelatin A product formed from skin, white connective tissue, or bone COLLAGEN. It is used as a protein food adjuvant, plasma substitute, hemostatic, suspending agent in pharmaceutical preparations, and in the manufacturing of capsules and suppositories. Gelafusal
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly

Related Publications

Shun-Fa Yang, and Yih-Shou Hsieh, and Chiao-Lin Lin, and Nan-Yung Hsu, and Hui-Ling Chiou, and Fen-Pi Chou, and Shu-Chen Chu
Matrix metalloproteinase-9 and urokinase-type plasminogen activator in varicose veins.
May 2003, Annals of vascular surgery,
Shun-Fa Yang, and Yih-Shou Hsieh, and Chiao-Lin Lin, and Nan-Yung Hsu, and Hui-Ling Chiou, and Fen-Pi Chou, and Shu-Chen Chu
Elevated plasma levels of urokinase plasminogen activator receptor in non-small cell lung cancer patients.
May 1997, European journal of cancer (Oxford, England : 1990),
Shun-Fa Yang, and Yih-Shou Hsieh, and Chiao-Lin Lin, and Nan-Yung Hsu, and Hui-Ling Chiou, and Fen-Pi Chou, and Shu-Chen Chu
Matrix metalloproteinase-9 and urokinase plasminogen activator mediate interleukin-1-induced neurotoxicity.
January 2008, Molecular and cellular neurosciences,
Shun-Fa Yang, and Yih-Shou Hsieh, and Chiao-Lin Lin, and Nan-Yung Hsu, and Hui-Ling Chiou, and Fen-Pi Chou, and Shu-Chen Chu
Urokinase plasminogen activator and plasminogen activator inhibitor type-1 in nonsmall-cell lung cancer: relation to prognosis and angiogenesis.
April 2007, Lung cancer (Amsterdam, Netherlands),
Shun-Fa Yang, and Yih-Shou Hsieh, and Chiao-Lin Lin, and Nan-Yung Hsu, and Hui-Ling Chiou, and Fen-Pi Chou, and Shu-Chen Chu
The influence of opioid peptides on matrix metalloproteinase-9 and urokinase plasminogen activator expression in three cancer cell lines.
January 2012, Molekuliarnaia biologiia,
Shun-Fa Yang, and Yih-Shou Hsieh, and Chiao-Lin Lin, and Nan-Yung Hsu, and Hui-Ling Chiou, and Fen-Pi Chou, and Shu-Chen Chu
Increased plasma levels of urokinase-type plasminogen activator with endometrial and cervical cancer.
August 1988, Obstetrics and gynecology,
Shun-Fa Yang, and Yih-Shou Hsieh, and Chiao-Lin Lin, and Nan-Yung Hsu, and Hui-Ling Chiou, and Fen-Pi Chou, and Shu-Chen Chu
Urokinase-type plasminogen activator induces BV-2 microglial cell migration through activation of matrix metalloproteinase-9.
July 2010, Neurochemical research,
Shun-Fa Yang, and Yih-Shou Hsieh, and Chiao-Lin Lin, and Nan-Yung Hsu, and Hui-Ling Chiou, and Fen-Pi Chou, and Shu-Chen Chu
Increased plasma matrix metalloproteinase-9 levels in migraineurs.
January 2008, Headache,
Shun-Fa Yang, and Yih-Shou Hsieh, and Chiao-Lin Lin, and Nan-Yung Hsu, and Hui-Ling Chiou, and Fen-Pi Chou, and Shu-Chen Chu
Aspirin Inhibits IKK-β-mediated Prostate Cancer Cell Invasion by Targeting Matrix Metalloproteinase-9 and Urokinase-Type Plasminogen Activator.
January 2017, Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology,
Shun-Fa Yang, and Yih-Shou Hsieh, and Chiao-Lin Lin, and Nan-Yung Hsu, and Hui-Ling Chiou, and Fen-Pi Chou, and Shu-Chen Chu
Elevated levels of circulating plasma matrix metalloproteinase 9 in non-small cell lung cancer patients.
January 1999, Clinical cancer research : an official journal of the American Association for Cancer Research,
Copied contents to your clipboard!